Business
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash. The claim method allows for MN-166 (ibudilast) to be administered alone or in combination with other active agents, including corticosteroids, NSAIDs, SSRIs, and more. The allowed claims cover oral administration, intravenous administration, subcutaneous injection, intramuscular injection, and inhalation administration. The allowed claims cover a wide range of doses, a range of different dosing frequencies, and a range of different treatment periods. Once issued, this patent is expected to expire no earlier than November 2042. Kazuko Matsuda, M.D., Ph.D., M.P.H., MediciNova’s Chief Medical Officer commented, “This additional patent for ibudilast provides additional opportunities for us to maintain exclusivity in areas where research is underway. We remain dedicated to addressing the complex and persistent health challenges posed by COVID-19 through key partnerships, such as our current collaboration with University Health Network in Canada, where a Phase 2/3 clinical trial in Long COVID is ongoing. We believe that ibudilast may offer hope to millions of patients suffering from post-COVID conditions, providing a versatile and effective therapeutic option. Since we have committed to move forward to apply New Drug Application when the study shows positive outcome, we plan to initiate the discussion with Health Canada when the RECLAIM study shows the positive data.” About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (...